<?xml version='1.0' encoding='utf-8'?>
<document id="28122787"><sentence text="A Physiologically-Based Pharmacokinetic Modeling Approach To Predict Drug-Drug Interactions of Sonidegib (LDE225) with Perpetrators of CYP3A in Cancer Patients."><entity charOffset="95-104" id="DDI-PubMed.28122787.s1.e0" text="Sonidegib" /></sentence><sentence text="Sonidegib (Odomzo) is an orally available Smoothened inhibitor for the treatment of advanced basal cell carcinoma"><entity charOffset="0-9" id="DDI-PubMed.28122787.s2.e0" text="Sonidegib" /><entity charOffset="11-17" id="DDI-PubMed.28122787.s2.e1" text="Odomzo" /><pair ddi="false" e1="DDI-PubMed.28122787.s2.e0" e2="DDI-PubMed.28122787.s2.e0" /><pair ddi="false" e1="DDI-PubMed.28122787.s2.e0" e2="DDI-PubMed.28122787.s2.e1" /></sentence><sentence text=" Sonidegib was found to be metabolized primarily by cytochrome P450 (CYP)3A in vitro"><entity charOffset="1-10" id="DDI-PubMed.28122787.s3.e0" text="Sonidegib" /></sentence><sentence text=" The effect of multiple doses of the strong CYP3A perpetrators, ketoconazole (KTZ) and rifampin (RIF), on sonidegib pharmacokinetics (PK) after a single 800 mg dose in healthy subjects was therefore assessed"><entity charOffset="64-76" id="DDI-PubMed.28122787.s4.e0" text="ketoconazole" /><entity charOffset="78-81" id="DDI-PubMed.28122787.s4.e1" text="KTZ" /><entity charOffset="87-95" id="DDI-PubMed.28122787.s4.e2" text="rifampin" /><entity charOffset="97-100" id="DDI-PubMed.28122787.s4.e3" text="RIF" /><entity charOffset="106-115" id="DDI-PubMed.28122787.s4.e4" text="sonidegib" /><pair ddi="false" e1="DDI-PubMed.28122787.s4.e0" e2="DDI-PubMed.28122787.s4.e0" /><pair ddi="false" e1="DDI-PubMed.28122787.s4.e0" e2="DDI-PubMed.28122787.s4.e1" /><pair ddi="false" e1="DDI-PubMed.28122787.s4.e0" e2="DDI-PubMed.28122787.s4.e2" /><pair ddi="false" e1="DDI-PubMed.28122787.s4.e0" e2="DDI-PubMed.28122787.s4.e3" /><pair ddi="false" e1="DDI-PubMed.28122787.s4.e0" e2="DDI-PubMed.28122787.s4.e4" /><pair ddi="false" e1="DDI-PubMed.28122787.s4.e1" e2="DDI-PubMed.28122787.s4.e1" /><pair ddi="false" e1="DDI-PubMed.28122787.s4.e1" e2="DDI-PubMed.28122787.s4.e2" /><pair ddi="false" e1="DDI-PubMed.28122787.s4.e1" e2="DDI-PubMed.28122787.s4.e3" /><pair ddi="false" e1="DDI-PubMed.28122787.s4.e1" e2="DDI-PubMed.28122787.s4.e4" /><pair ddi="false" e1="DDI-PubMed.28122787.s4.e2" e2="DDI-PubMed.28122787.s4.e2" /><pair ddi="false" e1="DDI-PubMed.28122787.s4.e2" e2="DDI-PubMed.28122787.s4.e3" /><pair ddi="false" e1="DDI-PubMed.28122787.s4.e2" e2="DDI-PubMed.28122787.s4.e4" /><pair ddi="false" e1="DDI-PubMed.28122787.s4.e3" e2="DDI-PubMed.28122787.s4.e3" /><pair ddi="false" e1="DDI-PubMed.28122787.s4.e3" e2="DDI-PubMed.28122787.s4.e4" /></sentence><sentence text=" These data were used to verify a physiologically-based pharmacokinetic (PBPK) model developed to 1) bridge the clinical drug-drug interaction (DDI) study of sonidegib with KTZ and RIF in healthy subjects to the marketed dose (200 mg) in patients 2) predict acute (14 days) versus long-term dosing of the perpetrators with sonidegib at steady state and 3) predict the effect of moderate CYP3A perpetrators on sonidegib exposure in patients"><entity charOffset="158-167" id="DDI-PubMed.28122787.s5.e0" text="sonidegib" /><entity charOffset="409-418" id="DDI-PubMed.28122787.s5.e1" text="sonidegib" /><entity charOffset="173-181" id="DDI-PubMed.28122787.s5.e2" text="KTZ" /><entity charOffset="181-189" id="DDI-PubMed.28122787.s5.e3" text="RIF" /><pair ddi="false" e1="DDI-PubMed.28122787.s5.e0" e2="DDI-PubMed.28122787.s5.e0" /><pair ddi="false" e1="DDI-PubMed.28122787.s5.e0" e2="DDI-PubMed.28122787.s5.e2" /><pair ddi="false" e1="DDI-PubMed.28122787.s5.e0" e2="DDI-PubMed.28122787.s5.e3" /><pair ddi="false" e1="DDI-PubMed.28122787.s5.e0" e2="DDI-PubMed.28122787.s5.e1" /><pair ddi="false" e1="DDI-PubMed.28122787.s5.e2" e2="DDI-PubMed.28122787.s5.e2" /><pair ddi="false" e1="DDI-PubMed.28122787.s5.e2" e2="DDI-PubMed.28122787.s5.e3" /><pair ddi="false" e1="DDI-PubMed.28122787.s5.e2" e2="DDI-PubMed.28122787.s5.e1" /><pair ddi="false" e1="DDI-PubMed.28122787.s5.e3" e2="DDI-PubMed.28122787.s5.e3" /><pair ddi="false" e1="DDI-PubMed.28122787.s5.e3" e2="DDI-PubMed.28122787.s5.e1" /></sentence><sentence text=" Treatment of healthy subjects with KTZ resulted in an increased sonidegib exposure of 2"><entity charOffset="65-74" id="DDI-PubMed.28122787.s6.e0" text="sonidegib" /><entity charOffset="36-44" id="DDI-PubMed.28122787.s6.e1" text="KTZ" /><pair ddi="false" e1="DDI-PubMed.28122787.s6.e1" e2="DDI-PubMed.28122787.s6.e1" /><pair ddi="false" e1="DDI-PubMed.28122787.s6.e1" e2="DDI-PubMed.28122787.s6.e0" /></sentence><sentence text="25- and 1" /><sentence text="49-fold (area under the curve0-240h and maximal concentration respectively), and RIF decreased exposure by 72% and 54%, respectively"><entity charOffset="81-83" id="DDI-PubMed.28122787.s8.e0" text="RIF" /></sentence><sentence text=" The model simulated the single- and/or multiple-dose PK of sonidegib (healthy subjects and patients) within âˆ¼50% of observed values"><entity charOffset="60-69" id="DDI-PubMed.28122787.s9.e0" text="sonidegib" /></sentence><sentence text=" The effect of KTZ and RIF on sonidegib in healthy subjects was also simulated well, and the predicted DDI in patients was slightly less and independent of sonidegib dose"><entity charOffset="30-39" id="DDI-PubMed.28122787.s10.e0" text="sonidegib" /><entity charOffset="156-165" id="DDI-PubMed.28122787.s10.e1" text="sonidegib" /><entity charOffset="15-23" id="DDI-PubMed.28122787.s10.e2" text="KTZ" /><entity charOffset="23-31" id="DDI-PubMed.28122787.s10.e3" text="RIF" /><pair ddi="false" e1="DDI-PubMed.28122787.s10.e2" e2="DDI-PubMed.28122787.s10.e2" /><pair ddi="false" e1="DDI-PubMed.28122787.s10.e2" e2="DDI-PubMed.28122787.s10.e3" /><pair ddi="false" e1="DDI-PubMed.28122787.s10.e2" e2="DDI-PubMed.28122787.s10.e0" /><pair ddi="false" e1="DDI-PubMed.28122787.s10.e2" e2="DDI-PubMed.28122787.s10.e1" /><pair ddi="false" e1="DDI-PubMed.28122787.s10.e3" e2="DDI-PubMed.28122787.s10.e3" /><pair ddi="false" e1="DDI-PubMed.28122787.s10.e3" e2="DDI-PubMed.28122787.s10.e0" /><pair ddi="false" e1="DDI-PubMed.28122787.s10.e3" e2="DDI-PubMed.28122787.s10.e1" /><pair ddi="false" e1="DDI-PubMed.28122787.s10.e0" e2="DDI-PubMed.28122787.s10.e0" /><pair ddi="false" e1="DDI-PubMed.28122787.s10.e0" e2="DDI-PubMed.28122787.s10.e1" /></sentence><sentence text=" At steady state, sonidegib was predicted to have a higher DDI magnitude with strong or moderate CYP3A perpetrators compared with a single dose"><entity charOffset="18-27" id="DDI-PubMed.28122787.s11.e0" text="sonidegib" /></sentence><sentence text=" Different dosing regimens of sondigeb with the perpetrators were also simulated and provided guidance to the current dosing recommendations incorporated in the product label" /><sentence text="" /></document>